PET Imaging of Peripheral Nerve Tumors

Assadi, Majid; Velez, Erik; Najafi, Mohammad Hosein; Matcuk, George R.; Gholamrezanezhad, Ali

doi:10.1016/j.cpet.2018.08.013

Cited by 13 publications

(9 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Depending on the threshold used, sensitivity and specificity are greater than 90% and 70%, respectively, for the detection of MPNSTs [ 30 , 31 , 32 ]. A tumor SUV of greater than 1.5-times that of normal hepatic tissue was also separately shown to be both a sensitive and specific indicator of MPNSTs [ 33 ].…”

Section: Characteristics Of Mpnsts and Differentiation From Plexiform Neurofibromasmentioning

confidence: 99%

Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

Knight

Santiago

et al. 2022

Children

View full text Add to dashboard Cite

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas (STS) with nerve sheath differentiation and a tendency to metastasize. Although occurring at an incidence of 0.001% in the general population, they are relatively common in individuals with neurofibromatosis type 1 (NF1), for whom the lifetime risk approaches 10%. The staging of MPNSTs is complicated and requires close multi-disciplinary collaboration. Their primary management is most often surgical in nature, with non-surgical modalities playing a supportive, necessary role, particularly in metastatic, invasive, or widespread disease. We, therefore, sought to provide a comprehensive review of the relevant literature describing the characteristics of these tumors, their pathophysiology and risk factors, their diagnosis, and their multi-disciplinary treatment. A close partnership between surgical and medical oncologists is therefore necessary. Advances in the molecular characterization of these tumors have also begun to allow the integration of targeted RAS/RAF/MEK/ERK pathway inhibitors into MPNST management.

show abstract

Section: Characteristics Of Mpnsts and Differentiation From Plexiform Neurofibromasmentioning

confidence: 99%

Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

Knight

Santiago

et al. 2022

Children

View full text Add to dashboard Cite

show abstract

“…Ultrasound or computed tomography (CT) may be useful in some patients for image-guided biopsies and bone scintigraphy can be helpful in assessing osseous involvement (11,15).…”

Section: Imaging Evaluation Of Pnsts -Differentiation Of Benign and Mmentioning

confidence: 99%

“…Therefore, it seems that the symptomatic PNFs with SUV ≥3.5 should be excised and lesions with SUV 2.5-3.5 should have precise clinical evaluation. FDG-PET/CT can be useful in the diagnosis of MPNST with specificity ranging from 72% to 95% and sensitivity ranging from 91% to 100% (15,18,19). The optimum time for measuring SUV in patients with symptomatic PNFs is 240 min after injection of FDG (19).…”

Section: Imaging Evaluation Of Pnsts -Differentiation Of Benign and Mmentioning

confidence: 99%

“…Whole-body hybrid PET/MRI is a viable alternative for evaluation of the potential occurrence of MPNSTs in NF1 patients, with sensitivity similar to that of PET/CT. Furthermore, X-ray dose reduction with PET/MR approaches 50% compared to PET/CT, a vital concern in this patient population with tumor suppressor gene impairment (15,20,21).…”

Section: Imaging Evaluation Of Pnsts -Differentiation Of Benign and Mmentioning

confidence: 99%

See 1 more Smart Citation

New Frontiers in Therapy of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Latest Evidence and Clinical Implications

et al. 2020

View full text Add to dashboard Cite

Almost all individuals with neurofibromatosis type 1 (NF1) develop peripheral nerve sheath tumors (PNSTs), mainly benign neurofibromas, however about 10% of PNSTs will undergo transformation to malignant peripheral nerve sheath tumors (MPNSTs). Surgical treatment of PNSTs has traditionally been regarded as a standard approach. The availability of new agents that target specific molecular pathways involved in the pathogenesis of PNST has led to a number of clinical trials, which resulted in increased chances for better survival and quality of life. This review presents the latest evidence and clinical implications for new therapies of PNSTs in patients with NF1 emphasizing the potential benefit from the use of Ras/MAPK pathway inhibitors, immunotherapy, chemotherapy or radiation therapy. We present evaluation of current knowledge on available treatment modalities. Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disease affecting about 1 in 3500 people worldwide (1). The hallmark clinical features of NF1 include multiple café-au-lait macules, neurofibromas, intertriginous freckling, osseous lesions, Lisch nodules and optic pathway gliomas. The disorder is typified by the presence of multisystem tumors, which carries a high risk of malignant transformation (2, 3). Nearly 100% of individuals with NF1 develop benign peripheral nerve sheath tumors (BPNSTs) and in approximately 30-50% of them atypical and plexiform neurofibromas (PNFs) are found. In about 10% of NF1 patients, neurofibromas may undergo transformation to malignant peripheral nerve sheath tumors (MPNSTs), which are highly aggressive. The differentiation between atypical neurofibroma and low grade MPNST is probably the most challenging issue in the pathology of peripheral nerve sheath tumors (PNSTs), particularly in NF1 patients. Clinically, atypical tumors often develop as extensive, slowly growing neoplasms, and pain can be a characteristic feature (4, 5). The poor response to currently available therapies underlines the need for more effective, targeted treatment methods for NF1-associated PNSTs (6, 7). In this review, we analyzed the latest evidence and clinical implications of new therapies of PNSTs in patients with NF1 emphasizing the importance of patient risk stratification to identify those who are likely to benefit from the use of Ras/MAPK pathway inhibitors, immunotherapy, chemotherapy or radiotherapy. We also analyzed the limitations of administering these therapies to all individuals with NF1-associated PNSTs together with future perspectives. Methodology PubMed searches were performed to identify potentially clinically relevant English-language studies published in the last 15 years. The searches were based on a combination of indexed terms and free text terms ("peripheral nerve sheath tumors"

show abstract

“…1 Tumor imaging, as a revolutionary technique for cancer diagnosis, is developing rapidly. 2 Among various imaging techniques, ultrasonography (US), 3 computed tomography (CT), 4 single-photon-emission CT (SPECT), 5 and positron-emission tomography (PET) 6 are routine modalities for tumor imaging in the clinic. PET, using radiotracers to visualize biological processes with the highest sensitivity, provides useful information to distinguish changes in cancer at the cellular level.…”

mentioning

confidence: 99%

Furin-Guided Intracellular ⁶⁸Ga Nanoparticle Formation Enhancing Tumor MicroPET Imaging

Wang¹,

Chen

Wu³

et al. 2019

Anal. Chem.

View full text Add to dashboard Cite

Positron-emission tomography (PET) is routinely used in the clinic for tumor imaging with ultrahigh sensitivity, but tumor-targeted PET imaging probes are quite few. In this work, we rationally designed a furin-responsive radiotracer Acetyl-Arg-Val-Arg-Arg-Cys(StBu)-Lys(DOTA-68Ga)-CBT (CBT- 68 Ga) and demonstrated that coinjection of the radiotracer with its cold analogue CBT-Ga instructed the formation of 68Ga nanoparticles in furin-overexpressing MDA-MB-468 cancer cells, which significantly enhanced microPET imaging of the tumor in vivo. In vitro results showed that CBT-Ga subjected to furin-initiated CBT-Cys condensation reaction and self-assembly to form the nanoparticles CBT-Ga-NPs with an average diameter of 258.3 nm. In vivo microPET imaging results indicate that the mice coinjected with CBT- 68 Ga and CBT-Ga, which warrants 68Ga nanoparticle formation in their MDA-MB-468 tumors, had a tumor/liver ratio 9.1-fold of that of the mice only injected with CBT- 68 Ga. We envisioned that, by replacing the RVRR substrate of CBT- 68 Ga with other enzyme-specific ones and using the strategy of intracellular nanoparticle formation, a series of radioactive probes could be developed for more sensitive and precise tumor microPET imaging in the near future.

show abstract

PET Imaging of Peripheral Nerve Tumors

Cited by 13 publications

References 66 publications

Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

New Frontiers in Therapy of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Latest Evidence and Clinical Implications

Furin-Guided Intracellular ⁶⁸Ga Nanoparticle Formation Enhancing Tumor MicroPET Imaging

Contact Info

Product

Resources

About

PET Imaging of Peripheral Nerve Tumors

Cited by 13 publications

References 66 publications

Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management

New Frontiers in Therapy of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Latest Evidence and Clinical Implications

Furin-Guided Intracellular 68Ga Nanoparticle Formation Enhancing Tumor MicroPET Imaging

Contact Info

Product

Resources

About

Furin-Guided Intracellular ⁶⁸Ga Nanoparticle Formation Enhancing Tumor MicroPET Imaging